Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine

Tirapazamine (TPZ) is a bioreductive drug that exhibits a high degree of se lective toxicity toward hypoxic cells, and at doses that are used clinicall y, little or no cell killing is observed in aerobic cells. Nonetheless, the effects of TPZ on aerobic tissues are still responsible for the dose limit ations on the clinical administration of this drug. Clinical side effects i nclude fatigue, muscle cramping, and reversible ototoxicity. We have invest igated TPZ-induced changes in the mitochondria in aerobically exposed cells as a potential mediator of these side effects. Our data show that aerobic administration of TPZ at clinically relevant doses results in a profound lo ss in the mitochondrial membrane potential (MMP). We show that loss in the MMP occurs in a variety of cell lines in vitro and also occurs in muscle ti ssues in vivo. The loss in MMP is temporary because recovery occurs within 2 h. TPZ is directly metabolized within mitochondria to a DNA-damaging form , and this metabolism leads to both the cell-killing effects of TPZ on aero bic cells at high doses and to the loss in MMP at clinically relevant doses . Using cell lines derived from genetically modified mice with a targeted d eletion in manganese superoxide dismutase, we have further distinguished th e phenotypic effects of TPZ in mitochondria at high toxic doses versus thos e at clinically relevant doses. We have investigated several potential mech anisms for this TPZ-induced loss in MMP. Our results indicate no change in the rate of cellular respiration in TPZ-treated cells. This implies that th e loss in MMP results from an inability of the inner mitochondrial membrane to sustain a potential across the membrane after TPZ treatment. Incubation of cells with an inhibitor of the mitochondrial permeability transition su ggests that the loss of MMP may result from the regulated opening of a larg e mitochondria channel.